A 3-Marker Index Improves the Identification of Iron Disorders in CKD Anaemia
Lucile Mercadal, Marie Metzger, Jean-Philippe Haymann, Eric Thervet, Jean-Jacques Boffa, Martin Flamant, François Vrtovsnik, Cédric Gauci, Marc Froissart, Bénédicte Stengel

To cite this version:
Lucile Mercadal, Marie Metzger, Jean-Philippe Haymann, Eric Thervet, Jean-Jacques Boffa, et al.. A 3-Marker Index Improves the Identification of Iron Disorders in CKD Anaemia. PLoS ONE, Public Library of Science, 2014, 9 (2), pp.e84144. <10.1371/journal.pone.0084144>. <hal-01367468>
A 3-Marker Index Improves the Identification of Iron Disorders in CKD Anaemia

Lucile Mercadal1,2, Marie Metzger1,3, Jean Philippe Haymann4,5, Eric Thervet6,7, Jean-Jacques Boffa5,8, Martin Flamant9,10, François Vrtovsnik9,11, Cédric Gauci12, Marc Froissart1,12, Bénédicte Stengel1,3, on behalf of the NephroTest Study Group

Abstract

Background: Iron disorders are common and complex in chronic kidney disease (CKD). We sought to determine whether a 3-marker index would improve the classification of iron disorders in CKD anaemia.

Methods: We studied the association between Hb level and iron indexes combining 2 or 3 of the following markers: serum ferritin (<40 ng/mL), transferrin saturation (TSAT<20%) and total iron binding capacity (TIBC<50 μmol/L) in 1011 outpatients with non-dialysis CKD participating in the Nephrotest study. All had glomerular filtration rates measured (mGFR) by 51Cr-EDTA renal clearance; 199 also had hepcidin measures.

Results: The TSAT-TIBC-ferritin index explained Hb variation better than indexes combining TSAT-TIBC or ferritin-TSAT. It showed hypotransferrinaemia and non-inflammatory functional iron deficiency (ID) to be more common than either absolute or inflammatory ID: 20%, 19%, 6%, and 2%, respectively. Hb was lower in all abnormal, compared with normal, iron profiles, and decreased more when mGFR was below 30 mL/min/1.73 m² (interaction p<0.0001). In patients with mGFR<30 mL/min/1.73 m², the Hb decreases associated with hypotransferrinaemia, non-inflammatory functional ID, and absolute ID were 0.83±0.16 g/dL, 0.51±0.18 and 0.89±0.29, respectively. Compared with normal iron profiles, hepcidin was severely depressed in absolute ID but higher in hypotransferrinaemia.

Conclusions: The combined TSAT-TIBC-ferritin index identifies hypotransferrinaemia and non-inflammatory functional ID as the major mechanisms of iron disorders in CKD anaemia. Both disorders were associated with a greater decrease in Hb when mGFR was <30 mL/min/1.73 m². Taking these iron profiles into account may be useful in stratifying patients in clinical trials of CKD anaemia and might improve the management of iron therapy.

Introduction

Anaemia is an early complication of chronic kidney disease (CKD) [1], associated with symptoms, potential need for blood transfusion and increased morbidity and mortality [2]. Relative erythropoietin (EPO) deficiency occurs rapidly with kidney function decline and is the main determinant of anaemia in advanced CKD (GFR<30 mL/min/1.73 m²) [3]. The efficacy of erythropoietin-stimulating agents (ESA), however, depends highly on iron bioavailability. Iron metabolism disorders are common and complex in CKD, but few studies have investigated their
relations with anaemia in early-stage CKD [4,5,6]. Two of these studies examined the relations between Hb and both transferrin saturation (TSAT) and ferritin. One showed bone marrow iron decreased as TSAT dropped, at thresholds of 25, 20 and 15% and as ferritin fell below 100 and 75 μg/l [4]. In the other study, anaemia was only related with TSAT [5]. Two other studies have also showed that iron disorders modify ESA response [6,7].

Clinical nephrology guidelines recommend use of serum ferritin and TSAT measure to guide iron therapy [8]. In haematology, however, the panel of blood tests to assess iron status also includes transferrin and total iron-binding capacity (TIBC), the latter directly derived from transferrin (TIBC = 25 × transferrin (g/L)). These results are usually combined to define different iron status profiles. The combined TIBC-TSAT index is used to discriminate iron deficiency (ID) from inflammatory syndrome related anaemia [9], while combining serum ferritin and TSAT [10] differentiates absolute vs functional ID (table 1). Each of these parameters represents an iron compartment. Ferritin measures iron stores. Transferrin is the main blood iron transporter and is required for iron uptake by the intestinal epithelia, while TSAT measures iron availability for erythropoiesis. TIBC measures the total amount of iron that can be transported by transferrin. Low iron stores together with low blood iron content define absolute iron deficiency, while high iron stores together with low blood iron content define functional iron deficiency. In this condition, the iron stores cannot be used. Finally, a transferrin deficiency with normal iron content has never been studied separately, but may also affect both iron use and Hb level. We therefore sought to determine whether combining these three iron tests would improve the identification of iron metabolism disorders as compared with the TSAT-ferritin index routinely used in the management of CKD anaemia.

We therefore compared the relations of various combinations of serum ferritin, TSAT and TIBC with haemoglobin level in 1011 patients with non-dialysis CKD to identify the combined index with the strongest impact on haemoglobin, independent of other anaemia risk factors. We also studied trends in these associations with kidney function decline.

### Methods

#### Population

NephroTest is a prospective hospital-based cohort study, enrolling adult outpatients with all diagnoses of CKD stages 1 to 5, who were not pregnant, not on dialysis or living with a kidney transplant, and who had been referred to any of three physiology departments for extensive clinical and laboratory work-ups [1]. All patients signed an informed consent at inclusion. Of 1,294 NephroTest patients included between January 2000 and December 2009, we excluded 78 who were treated with ESA or intravenous iron, 125 without treatment information, and 80 with missing Hb or iron test values. This analysis thus covered 1011 patients. The NephroTest study design was approved by the relevant ethics committee (DGRI CCTIRS MG/CP09.503).

#### Laboratory measures

Glomerular filtration rates were measured (mGFR) by renal clearance of 51Cr-EDTA in all patients. We also measured Hb, mean corpuscular volume, serum albumin, serum folate, C-reactive protein, and urinary protein-to-creatinine ratio (UPCR). EPO was measured in a subgroup of 251 patients and hepcidin in 188 patients; 152 had both measurements. Endogenous EPO levels were determined in serum (100 μL) with the Quantitine IVD Epo double-antibody sandwich ELISA method from R&D Systems (Minneapolis, MN). Hepcidin was measured by an electrochemiluminescent test developed at Amgen, Thousand Oaks, CA [10].

### Table 1. Iron status index combining ferritin, transferrin saturation (TSAT) and total iron-binding capacity (TIBC).

| Iron Indices                  | Threshold 20.50.40 |                      | Threshold 15.45.20 |                      | Threshold 25.55.100 |                      |
|------------------------------|--------------------|----------------------|--------------------|----------------------|--------------------|----------------------|
|                              | TSAT %             | TIBC μmol/L          | Ferritin ng/ml     | TSAT %              | TIBC μmol/L          | Ferritin ng/ml     |
| TSAT-Ferritin index 10       |                    |                      |                    |                      |                    |                      |
| Normal                       | ≥20                | -                    | -                  | ≥15                 | -                  | -                    |
| Absolute iron deficiency     | <20                | -                    | <40                | <15                 | -                  | <20                 |
| Functional iron deficiency   | <20                | -                    | ≥40                | <15                 | -                  | ≥20                 |
| TSAT-TIBC index              |                    |                      |                    |                      |                    |                      |
| Normal                       | ≥20                | ≥50                  | ≥15                | ≥45                 | ≥25                | ≥55                 |
| Iron deficiency              | <20                | ≥50                  | <15                | ≥45                 | <25                | ≥55                 |
| Inflammatory iron deficiency | <20                | <50                  | <15                | <45                 | <25                | <55                 |
| Hypotransferrinaemia         | ≥20                | <50                  | ≥15                | <45                 | ≥25                | <55                 |
| TSAT-TIBC-ferritin index     |                    |                      |                    |                      |                    |                      |
| Normal                       | ≥20                | ≥50                  | ≥15                | ≥45                 | ≥25                | ≥55                 |
| Absolute iron deficiency     | <20                | ≥50                  | <40                | <15                 | ≥45                | <20                 |
| Noninflammatory functional iron deficiency | <20 | ≥50 | ≥40 | ≥15 | ≥45 | ≥20 |
| Inflammatory functional iron deficiency | <20 | <50 | ≥40 | <15 | <45 | ≥20 |

*Each combination of iron marker and their threshold values is tested in this study.*

Total iron-binding capacity (TIBC) in μmol/L was calculated as 25 × transferrin (g/L). Transferrin saturation (TSAT) was calculated as serum iron(TIBC × 100%).

[doi:10.1371/journal.pone.0084144.t001]
## Table 2. Patient characteristics by gender.

|                        | Overall          | Men             | Women            |
|------------------------|------------------|-----------------|------------------|
| No of patients         | 1011             | 718             | 293              |
| Age (Years), mean ± sd | 60.2±14.7        | 60.7±14.6       | 58.9±14.9        |
| Sub-Saharan African origin, % | 8.1             | 10.2            | 4.3              |
| Diabetes mellitus, %    | 26.0             | 29.9            | 23.2             |
| with diabetic glomerulopathy | 15.2         | 16.7            | 11.6             |
| with other nephropathy types | 12.8       | 13.2            | 11.6             |
| Body Mass Index (kg/m²), mean ± sd | 26.5±4.9 | 26.7±4.5        | 25.9±5.9         |
| Systolic BP mmHg, median [IQR] | 136 [124–150] | 138 [125–152] | 132 [118–148]   |
| Diastolic BP mmHg, median [IQR] | 75 [68–83] | 76 [69–84] | 72 [65–79]       |
| mGFR mL/min/1.73 m², median [IQR] | 35.9 [25.6–48.9] | 37.4 [27.1–51.0] | 34.6 [23.9–49.5] |
| CKD stages, %          |                  |                 |                  |
| 1–2 (mGFR≥60 ml/min/1.73 m²) | 15.3          | 15.5            | 15.0             |
| 3a (45–60)             | 19.3             | 20.6            | 16.0             |
| 3b (30–45)             | 31.0             | 32.0            | 28.3             |
| 4 (15–30)              | 28.2             | 25.9            | 33.8             |
| 5 (<15)                | 6.2              | 6.0             | 6.8              |
| eGFR CKDEPI mL/min/1.73 m², median [IQR] | 36.9 [25.9–50.8] | 37.2 [26.3–51.5] | 35.9 [24.9–49.7] |
| UPCr mg/mmol, median [IQR] | 32.3 [13.5–113.5] | 33.7 [12.8–117.8] | 31.6 [15.0–102.0] |
| Total cholesterol (mmol/L), mean ± sd | 5.0±1.2     | 4.9±1.2         | 5.3±1.2          |
| Serum albumin (g/L), mean ± sd | 39.3±5.0    | 39.8±5.0        | 38.2±4.6         |
| C-reactive protein>8 mg/L, % | 12.0         | 12.0            | 11.9             |
| Hb (g/dL), mean ± sd   | 12.6±1.6        | 12.9±1.6        | 11.8±1.4         |
| WHO anaemia, %         | 53.1             | 51.9            | 56.0             |
| Ferritin ng/mL, median [IQR] | 128.8 [68.2–219.0] | 155.1 [81.2–238.8] | 91.2 [41.9–155.8] |
| TSAT, %                | 26.1±10.0        | 26.7±10.0       | 24.4±9.7         |
| TIBC μmol/L, mean ± sd | 56.7±10.6        | 56.3±10.2       | 57.6±11.5        |
| Oral iron therapy, %   | 9.0              | 6.4             | 15.4             |
| RASI, %                | 79.1             | 82.2            | 71.7             |

**Abbreviations:** BP, blood pressure; mGFR, measured glomerular filtration rate; eGFR CKDEPI, estimated glomerular filtration rate using the Chronic Kidney Disease Epidemiology Collaboration equation; UPCr, urinary protein-to-creatinine ratio; Hb, haemoglobin; WHO-anaemia, defined according to World Health Organization as Hb level <13 g/dL for men (<12 g/dL for women); TSAT, transferrin saturation; TIBC, transferrin iron-binding capacity; RASI, renin-angiotensin system inhibitors. TIBC (μmol/L) was calculated as 25 × transferrin (g/L). TSAT was calculated as serum iron/TIBC × 100.

doi:10.1371/journal.pone.0084144.t002

### Assessment of iron status

Serum iron (DxC800 Beckman-Coulter, ferrozine, emitted light 560 nm), ferritin (BN-Siemens, N-latex ferritin immunonephelometry), and transferrin (BN-Siemens, N Antiserum antitransferrin immunonephelometry) were measured in all patients. TIBC (μmol/L) was calculated as 25 × transferrin (g/L). TSAT (%) was calculated as serum iron/TIBC × 100.

We studied three different iron indexes: the combined ferritin-TSAT and TIBC-TSAT indexes described above [9,10], and one combining ferritin, TSAT and TIBC. The latter discriminated five profiles: normal, absolute ID, non-inflammatory functional ID, inflammatory functional ID, and hypotransferrinaemia (Table 1). For each index, we studied three different cut-off points. TSAT<20% and TIBC<50 μmol/L were chosen first, as the lower limit of these normal values, and ferritin<40 ng/mL, because it is the level usually recommended for diagnosing absolute ID [10]. We then used more specific or more sensitive definitions: ferritin<20 ng/mL, TSAT<15% and TIBC<45 μmol/L, and ferritin<100 ng/mL, TSAT<25%, and TIBC<55 μmol/L.

### Statistical analyses

We first studied factors associated with Hb levels, treated as a continuous or a categorical variable, by gender. Anaemia was defined according to either KDOQI (Hb<11 g/dL) or WHO gender-specific criteria (Hb<12/13 g/dL in women/men). Crude associations were analyzed with the Kruskal-Wallis and Cochran-Armitage tests, as appropriate. Secondly, we plotted levels of mean Hb and of each iron marker according to mGFR level (≥60, 45–59, 30–44, 15–29, and <15 mL/min/1.73 m²), by gender. Linear regression models were used to test interactions with gender in the relations between mGFR and these markers. Because ferritin is not normally distributed, this variable was log-transformed in this analysis (Figure S1).

We then ran multivariate regression analyses to study the effect of the different iron markers alone or in combinations of 2 or 3 markers on Hb concentration after adjusting for well-established anaemia risk factors and potential confounders [11]. Variables that were not associated with Hb (p>0.2) were not included in final model. Moreover, we verified that correlation coefficients
Table 3. Factors associated with haemoglobin level and anaemia by gender.

|                      |         | WHO anaemia% | p-value |         | WHO anaemia% | p-value |         | KDOQI anaemia% | p-value |         | KDOQI anaemia% | p-value |
|----------------------|---------|--------------|---------|---------|--------------|---------|---------|---------------|---------|---------|---------------|---------|
|                      | Men     | mean ± sd    | p-value | Women   | mean ± sd    | p-value |         |               |         |         |               |         |
| N                    |         |              |         | N       |              |         |         |               |         |         |               |         |
| Age classes          |         |              |         |         |              |         |         |               |         |         |               |         |
| <55 yr               | 230     | 13.2 ± 1.8   | 0.001   | 111     | 11.7 ± 1.5   | 0.8     |         |               |         |         |               |         |
| 55–70 yr             | 257     | 12.8 ± 1.5   | 0.101   | 95      | 11.8 ± 1.3   | 0.5     |         |               |         |         |               |         |
| ≥70 yr               | 231     | 12.7 ± 1.5   | 0.113   | 87      | 11.7 ± 1.3   | 0.8     |         |               |         |         |               |         |
| African origin       |         |              |         |         |              |         |         |               |         |         |               |         |
| No                   | 616     | 12.9 ± 1.6   | 0.01    | 265     | 11.8 ± 1.4   | 0.1     |         |               |         |         |               |         |
| Yes                  | 70      | 12.7 ± 1.7   |         | 12      | 11.2 ± 1.1   |         |         |               |         |         |               |         |
| BMI                  |         |              |         |         |              |         |         |               |         |         |               |         |
| <25                  | 263     | 12.7 ± 1.6   | 0.02    | 153     | 11.7 ± 1.4   | 0.9     |         |               |         |         |               |         |
| 25–30                | 312     | 12.9 ± 1.6   | 0.07    | 75      | 11.8 ± 1.3   | 0.3     |         |               |         |         |               |         |
| ≥30                  | 143     | 13.2 ± 1.6   | 0.98    | 65      | 11.8 ± 1.4   | 0.7     |         |               |         |         |               |         |
| mGFR (mL/min/1.73 m²) |         |              |         |         |              |         |         |               |         |         |               |         |
| ≤60                  | 111     | 13.9 ± 1.5   | <0.0001 | 252     | 12.2 ± 1.3   | <0.0001 |         |               |         |         |               |         |
| 45–60                | 148     | 13.4 ± 1.4   | 0.34    | 47      | 12.3 ± 1.0   | 0.42    |         |               |         |         |               |         |
| 30–45                | 230     | 12.9 ± 1.5   | 0.87    | 47      | 11.9 ± 1.4   | 0.50    |         |               |         |         |               |         |
| 15–30                | 186     | 12.1 ± 1.3   | 0.18    | 99      | 11.3 ± 1.3   | 0.69    |         |               |         |         |               |         |
| <15                  | 43      | 11.2 ± 1.4   | 0.41    | 20      | 11.2 ± 1.6   | 0.75    |         |               |         |         |               |         |
| UPCR (mg/mmol)       |         |              |         |         |              |         |         |               |         |         |               |         |
| ≤30                  | 319     | 13.2 ± 1.5   | <0.0001 | 42.3    | 12.1 ± 1.2   | 0.001   | 45.1    | 0.01     | 17.3    | 0.01     |         |         |
| 30–300               | 288     | 12.6 ± 1.6   | 0.59    | 116     | 11.5 ± 1.5   | 0.63    | 63.8    | 0.36     |         |         |         |         |
| >300                 | 60      | 12.2 ± 1.4   | 0.71    | 23      | 11.6 ± 1.3   | 0.66    | 69.6    | 0.30     |         |         |         |         |
| Albuminaemia (g/L)   |         |              |         |         |              |         |         |               |         |         |               |         |
| <40                  | 355     | 12.6 ± 1.6   | <0.0001 | 61.1    | 11.6 ± 1.4   | 0.02    | 59.7    | 0.10     | 30.9    | 0.08     |         |         |
| ≥40                  | 357     | 13.2 ± 1.6   | 0.78    | 99      | 12.0 ± 1.2   | 0.45    | 49.5    | 0.21     |         |         |         |         |
| C-Reactive Protein (mg/L) | 609 | 13.0 ± 1.6 | 0.0011 | 49.8 | 11.8 ± 1.4 | 0.009 | 52.4 | 0.005 | 25 | 0.01 | | |
| ≥8                   | 86      | 12.3 ± 1.5   | 0.67    | 35      | 11.4 ± 1.1   | 0.74    | 743     | 0.34     |         |         |         |         |
| missing              | 23      | 12.5 ± 1.4   | 0.52    | 10      | 10.8 ± 1.4   | 0.8     | 80      | 0.60     |         |         |         |         |
| Folates (ng/mL)      |         |              |         |         |              |         |         |               |         |         |               |         |
| <54                  | 251     | 13.2 ± 1.6   | <0.0001 | 462    | 11.9 ± 1.6   | 0.003   | 47.3    | 0.0006   | 29.7    | 0.5      |         |         |
| 5.4–8.3              | 224     | 13.1 ± 1.5   | 0.46    | 96      | 12.0 ± 1.3   | 0.45    | 48.8    | 0.18     |         |         |         |         |
| ≥8.3                 | 216     | 12.4 ± 1.6   | 0.18    | 115     | 11.4 ± 1.2   | 0.68    | 68.4    | 0.33     |         |         |         |         |
| missing              | 27      | 12.7 ± 1.3   | 0.74    | 9       | 11.4 ± 1.0   | 0.77    | 77.8    | 0.22     |         |         |         |         |
| Current smoking      |         |              |         |         |              |         |         |               |         |         |               |         |
| No                   | 627     | 12.8 ± 1.6   | 0.3     | 112     | 11.7 ± 1.4   | 0.2     | 57.8    | 0.10     | 27.7    | 0.07     |         |         |
| Yes                  | 91      | 13.1 ± 1.7   | 0.11    | 37      | 12.0 ± 1.5   | 0.43    | 43.2    | 0.24     |         |         |         |         |
between independent variables were less than 0.5 to avoid any problem of colinearity in our models.

The best iron index was defined as the one producing the Hb model with the best fit after adjustment for confounders. We used the Bayesian Information Criterion (BIC or Schwartz criteria) and the Akaike information Criterion (AIC) to compare non-nested models. The model with the lowest BIC or AIC is considered the best.

We additionally tested interactions with both gender and mGFR, treated as a continuous or a categorical variable < or ≥30 mL/min/1.73 m² in the relations between Hb and the iron indexes. Similarly, to validate the relevance of the various levels chosen (ferritin 40 ng/ml, TSAT 20%, and TIBC 50 μmol/L), we compared models including iron indexes with more specific or more sensitive definitions, as described above.

Finally, we studied patient characteristics and measurements according to the best combined iron index. We used ANOVA to compare quantitative variables and logistic regression for qualitative ones and defined statistical significance as P<0.05. We performed statistical analyses with SAS 9.2 (SAS Institute, Cary, NC).

Results

Patient characteristics

Table 2 summarizes the characteristics of the NephroTest cohort patients by gender. More than half had WHO-defined anaemia. Vascular nephropathy, primary glomerulonephritis, and diabetic nephropathy (either biopsy-proven or defined by a history of albuminuria >300 mg/g, or creatininuria or retinopathy or/and neuropathy) accounted for two thirds of the cases.

Factors associated with haemoglobin level and anaemia, by gender

Hb significantly decreased with age in men but not in women (Table 3). For both genders, Sub-Saharan African origin, diabetic nephropathy, lower mGFR, higher proteinuria and higher CRP levels were associated with lower Hb levels and higher prevalence of anaemia. In men, low serum albumin was also associated with higher anaemia prevalence. Of note, there was an inverse association between serum folate and Hb. Hb levels did not differ between patients treated with either single or double RAS blockade or folate and those not so treated, but mean Hb was slightly lower in patients receiving oral iron therapy or diuretics (data not shown).

Levels of haemoglobin and iron markers according to mGFR level, by gender

Hb levels decreased faster with mGFR decline in men (interaction p=0.001) than women, and reached the levels in women at mGFR<15 mL/min/1.73 m² (Figure 1). The relation between ferritin and mGFR varied by gender (interaction p=0.01), increasing with decreasing mGFR only in women (p=0.008). The TSAT level was lower in women than men (p=0.001), but did not change with mGFR (p=0.2). In contrast, TIBC was slightly higher in women (p=0.02) and decreased similarly and significantly with mGFR decline in both genders (p<0.0001).

Relations between iron metabolism indexes and Hb level

There was no interaction with gender in the relations between Hb and any of the iron indexes. In contrast, there were significant interactions with mGFR in the relations between Hb and each
iron test as well as the combined indexes (all p<0.001). All multivariate analyses were therefore run by mGFR level (Table 4), but irrespective of gender. All abnormal iron status profiles were associated with a greater Hb decrease than the normal status when mGFR was below 30 mL/min/1.73 m². The Hb decline for absolute ID, non-inflammatory functional ID, and hypotransferrinaemia, defined by the 20-50-40 TSAT-TIBC-ferritin index, was 0.89±0.29, 0.51±0.18 and 0.83±0.16 g/dL under 30 mL/min/1.73 m², respectively (Table 4). Of all the iron indexes we tested, this index produced the Hb model with the lowest AIC value (Table 4). Using a more specific definition with thresholds of 15-45-20, respectively, produced a much higher BIC, as did using a more sensitive definition with thresholds of 25-55-100 (BIC = 3530, data not shown). However, AIC values were close between the best model and the model including the TSAT-TIBC index with the 20–50 thresholds. The BIC values for the relation of Hb levels to ferritin, TSAT and TIBC, considered separately, were substantially higher (all above 3530, data not shown) than that for the combined TSAT-TIBC-ferritin index. Therefore, the combined TSAT-TIBC-ferritin index, with thresholds of 20%, 50 μmol/L and 40 ng/mL, was the one with the strongest association with Hb decreases.

Prevalence of iron metabolism disorders by gender and associated factors

The overall prevalences of each iron metabolism disorder as defined by the TSAT-TIBC-ferritin combined index were as follows: 6% for absolute ID, 19% for non-inflammatory functional ID, 2% for inflammatory functional ID, and 20% for isolated
hypotransferrinaemia (Table 5). These prevalences were similar in men and women, except for absolute ID, which was four times more common in women (13.3%) than men (2.9%) (Figure 2a). Prevalences of non-inflammatory functional ID and hypotransferrinaemia steadily increased with decreasing mGFR, while that of absolute ID did not (Figure 2b). Compared with patients with no iron disorder, those with non-inflammatory functional ID had higher BMI and CRP values and lower serum albumin levels (Table 6). Patients with hypotransferrinaemia were younger, had higher BMI and CRP values and lower serum albumin levels (Table 6).

Hepcidin was severely depressed in absolute ID and increased in hypotransferrinaemia, but did not differ from normal for other disorders. In those measured for EPO, its level was significantly increased only in absolute ID (Table 6).

Discussion

This study showed that a 3-marker index combining ferritin with TSAT and TIBC better demonstrates the impact of the various iron metabolism disorders on Hb levels than individual iron tests or 2-marker indexes do. This is the first study to examine this index and its relation to Hb in a cohort of CKD patients. This combined index revealed two main pathologic mechanisms, namely, non-inflammatory ID and hypotransferrinaemia, and showed that the roles of inflammatory and absolute ID were minor. Moreover, the relations between these iron profiles and decrease in Hb tended to strengthen when mGFR was below 30 mL/min/1.73 m². Our finding that the magnitude of the Hb decrease associated with isolated hypotransferrinaemia was as high as that for other iron profiles provides new insight into CKD anaemia.

Absolute ID was uncommon, but its prevalence depended highly on the ferritin cut-off used to define ID. Using a ferritin level <100 ng/mL and TSAT <20%, Fishbane et al found about 25% of the men with estimated GFR <60 mL/min/1.73 m² had absolute ID, and more than 60% of women, i.e., more than 5 times more than here [5]. While 100 ng/mL is considered the lower acceptable limit in CKD patients, choosing 40 ng/mL for ferritin more specifically identifies patients with ID due to blood loss [12]. We also observed that this cut-off explained Hb variability best. In patients with inflammation, a range of 50 to 100 ng/mL has been suggested for this cut-off [12,13]. Given that the combined TSAT-TIBC-ferritin index classifies patients with
inflammatory iron status apart from the other categories, a low ferritin cut-off value seems more justified for the definition of absolute ID in the combined index. Like others [5,14], we found absolute ID to be much more common in women. As expected, this profile was associated with the lowest mean value for hepcidin.

Functional ID without inflammation was one of the most frequent iron disorders. Its prevalence steadily increased with CKD progression and its association with Hb decline also strengthened. Compared with inflammatory ID, this category included patients with normal transferrin, lower C-reactive protein level and higher albuminemia. On the other hand, inflammatory ID was relatively rare in our cohort. The prevalence we observed was similar to the 3% prevalence of inflammatory iron status evaluated by bone marrow parameters in non-dialysis CKD patients [4]. However, from a clinical point of view, its prevalence is high during acute complications. Inflammation affects Hb via the

![Figure 2](https://example.com/figure2.png)

**Figure 2. Iron profiles distribution according to gender (2a) and mGFR (2b).**

doi:10.1371/journal.pone.0084144.g002

**Table 5.** Distribution of patients according to the TSAT-ferritin index [10] (rows), the TSAT-TIBC index (columns) and the combined TSAT-TIBC-ferritin index (cells).

| TSAT-TIBC index | Normal | Iron deficiency | Inflammatory syndrome | Hypotransferrinaemia | Total |
|-----------------|--------|-----------------|-----------------------|----------------------|-------|
| **TSAT-ferritin index** |        |                 |                       |                      |       |
| Normal          | 538 (53.2) | 0 | 0 | 202 (19.9) | 740 |
| Absolute ID     | 0 | 60 (5.9) | 2 (0.2) | 0 | 62 |
| Functional ID   | 0 | 188 (18.6) | 21 (2.1) | 0 | 209 |
| **Total**       | 538 | 248 | 23 | 202 | 1011 |

Data are expressed as n (%).

Cells include numbers (%) for the five iron profiles defined by the combined ferritin-TSAT-TIBC index: normal, absolute ID, noninflammatory functional ID, inflammatory functional ID, and hypotransferrinaemia.

Abbreviations: ID, iron deficiency; TSAT, transferrin saturation; TIBC, transferrin iron-binding capacity.

**TSAT-Ferritin index** normal iron status defined as TSAT>20%, absolute ID as TSAT<20% and ferritin<40 ng/ml, and functional ID as TSAT<20% and ferritin≥40 ng/ml.

**TSAT-TIBC index** normal iron status defined as TIBC<50 μmol/L and TSAT>20%, ID as TIBC<50 μmol/L and TSAT<20%, inflammatory syndrome as TIBC<50 μmol/L and TSAT<20%, and hypotransferrinaemia as TIBC<50 μmol/L and TSAT≥20%.

doi:10.1371/journal.pone.0084144.t005
iron pathway. Adjustment for CRP controlled for the impact of inflammation via the non-iron pathway. An increase of hepcidin with CKD decline and inflammation was expected to be one of the main mechanisms implicated in these functional ID profiles [15]. However, we failed to find any association between hepcidin and these profiles.

The second most frequent pathologic iron status was hypotransferrinaemia with both normal TSAT and ferritin. This category was created to separate the 202 patients (19.9%) with isolated low transferrin from those with all normal iron tests. An original finding of this study is that this category is associated with an Hb decrease as low as in the three other categories, for it validates the abnormality of isolated hypotransferrinaemia. The decreased transferrin level may have misleadingly normalized TSAT, but serum iron and ferritin level were noticeably high in this patient group and reflected normal iron reserves. This iron profile was also seen in hemodialysis patients [16]. Isolated hypotransferrinaemia would be mostly secondary to malnutrition [17] and urinary loss [18] and different from that observed in inflammatory ID. This hypothesis is consistent with the lower BMI and albuminemia levels in patients with hypotransferrinaemia compared with normal profiles, together with a strong proteinuria increase and only a slight CRP increase compared to the inflammatory ID profile. In addition, a decrease in bone marrow activity may modify the transferrin metabolism [19]. Transferrin decreased as GFR fell in our cohort. This finding corroborates the results of the MDRD study [20]. Protein and energy intake did not fully explain the transferrin trends in that study, although they did explain other nutritional parameters, such as albuminemia [20]. Nutrition status and bone marrow activity, which both worsen with CKD progression, can influence transferrin levels.

To our knowledge, a high prevalence of isolated hypotransferrinaemia has never before been shown in CKD patients, nor its association with anaemia. Malnutrition might be the underlying cause of anaemia in this group, but hypotransferrinaemia may also play a direct role in anaemia occurrence. A transferrin deficiency can induce anaemia per se as seen in human atransferrinaemia and in animal models [21,22]. Atransferrinaemia is a rare autosomal recessive disease that causes hypochromic anaemia [23]. These patients have no iron staining in the blood marrow but nonetheless have iron overload in the liver and spleen. Iron normally internalized via the transferrin pathway cannot be delivered to

Table 6. Patient characteristics and measures according to iron status profile.

| Hypotransferrinaemia | p-value | Normal | Absolute ID | Noninflammatory functional ID | Inflammatory functional ID |
|----------------------|---------|--------|-------------|-------------------------------|--------------------------|
| No                   |         | 538    | 62          | 188                           | 21                       |
| Women (%)            |         | 26.8   | 64.5*       | 28.7                          | 23.8                     |
| Age (years)          |         | 60.9±14.3 | 54.5±17.0*  | 62.9±12.5                     | 60.9±15.0                |
| for men              |         | 60.9±14.4 | 59.0±15.3   | 63.0±12.2                     | 62.8±15.1                |
| for women            |         | 60.9±13.8 | 52.0±17.5*  | 62.6±13.3                     | 54.9±14.2                |
| Subsaharian African origin (%) |         | 7.4     | 6.7         | 11.0                          | 0.0                      |
| Diabetic nephropathy (%) |       | 11.7    | 14.5        | 16.5                          | 19.1                     |
| Body mass index (kg/m²) |       | 26.5±4.5 | 25.6±5.5   | 27.7±5.8*                     | 27.1±6.0                 |
| UPCR (mg/mmol)       |         | 27.3 [12.9–86.4] | 30.5 [13.1–87.7] | 32.3 [12.5–123.5] | 166.9 [26.4–230.0]* |
| mGFR mL/min per 1.73 m² |         | 42.3±19.4 | 41.2±19.4  | 37.9±17.1*                    | 34.3±19.6*               |
| C-reactive protein >8 mg/L |       | 7.3     | 16.7*       | 20.9*                         | 45.0*                    |
| Albumin (g/L)        |         | 40.4±4.2 | 38.0±4.0*   | 38.6±5.1*                     | 35.0±7.2*                |
| Hb (g/dL)            |         | 13.0±1.5 | 11.6±1.7*   | 12.3±1.6*                     | 12.0±1.4*                |
| WHO anaemia (%)      |         | 42.9    | 72.6*       | 59.6*                         | 71.4*                    |
| Men                  |         | 42.4    | 68.2*       | 61.2*                         | 75.0*                    |
| Women                |         | 44.4    | 75.0*       | 55.6                          | 60.0                     |
| Serum iron (µmol/L)  |         | 16.8±4.5 | 8.3±2.6*   | 9.8±2.1*                      | 7.3±1.4*                 |
| Ferritin (ng/mL)     |         | 141 [76–234] | 22 [12–31]* | 107 [62–178]*                | 171 [100–217]           |
| Mean Corpuscular volume (fl) |       | 90.6±5.7 | 86.2±6.0*   | 88.3±5.8*                    | 88.6±4.5                 |
| Mean Corpuscular Hb (pg) |       | 30.3±2.1 | 28.3±2.4*   | 29.4±2.2*                    | 29.5±1.9                 |
| Hepcidin (ng/mL) No  |         | 97      | 12          | 37                            | 4                        |
| Erythropoietin (IU/L) No |       | 29.3 [18.9–42.3] | 4.4 [0.7–11.2]* | 22.2 [16.1–41.9] | 26.1 [6.5–69.1] |
| § partial p-value     |         | 8.5 (5.8–12.1) | 11.6 (8.2–17.6)* | 9.4 (7.2–11.7) | 7.9 (5.9–10.4) |

Data are expressed as means ± SD, median (interquartile range) or %.
* P-value of the comparison with the normal category < 0.05.

Abbreviations: UPCR, urinary protein-to-creatinine ratio; mGFR, measured glomerular filtration rate; Hb, haemoglobin; WHO anaemia, defined according to World Health Organization as Hb level < 13 g/dL for men (< 12 g/dL for women); TSAT, transferrin saturation; TIBC, transferrin iron-binding capacity; ID, iron deficiency.

Definitions: Normal iron status (TSAT ≥ 20% and TIBC ≥ 50 µmol/L), absolute ID (ferritin < 40 ng/mL, TSAT < 20%, TIBC ≥ 50 µmol/L), non-inflammatory functional ID (ferritin ≥ 40, TSAT < 20, TIBC ≥ 50), inflammatory functional ID (ferritin ≥ 40, TSAT < 20, TIBC < 50), and hypotransferrinaemia (TSAT ≥ 20, TIBC < 50).

doi:10.1371/journal.pone.0084144.t006
erythrocyte precursors. Plasma or purified apotransferrin infusions normalize their Hb levels [24] and increase their hepcidin concentrations [25,26]. Patients with hypotransferrinaemia in our cohort share some features of human atransferrinaemia and of the hypotransferrinaemia animal models, in particular, normal serum iron and normal to high iron stores. However, in contrast to animal models, the hepcidin level was not below normal in this patient group, but rather slightly above normal. Given the cross-sectional design of our study and the short lifetime of hepcidin, it is possible that we missed a transient phase of its decrease.

The major strengths of our study include its large sample size of well-phenotyped patients with a wide range of renal function, a large number of laboratory measurements, and its use of measured GFR. The study power was sufficient to conduct subgroup analyses according to mGFR and to show significant associations with Hb changes for all iron status profiles, except the small group of 21 patients with inflammatory ID. The higher number of men than women in this cohort reflects the well-established higher risk for CKD in men, but the lack of interaction with gender in the associations between iron status and Hb allows us to apply results to both genders.

This study also has limitations, however, related to its cross-sectional design that prevents causal inferences. For example, whether hypotransferrinaemia truly caused hepcidin to increase or was preceded by a decrease in hepcidin cannot be answered. The second limitation is linked to the basic evaluation of iron metabolism. Iron stores can be evaluated more accurately in bone marrow; erythrocyte precursor iron uptake is influenced by transferrin receptors and can be assessed more exactly by the percentage of hypochromic reticulocytes. Those are however less frequently used, and our purpose was to show how we may improve the use of routine iron tests in CKD anemia.

Altogether, the TSAT-TIBC-ferritin index developed in this study clarifies the different iron metabolism disorders at work in CKD anemia. It was shown to be associated with decreased Hb levels more strongly than either each iron marker taken separately or previous combined iron indexes. This index showed non-inflamatory functional ID and hypotransferrinaemia to be the major mechanisms of iron disorders in CKD anemia. These findings should encourage clinical trials to study iron therapy and ESA responsiveness according to patient iron profile. We may hypothesize, for example, that higher iron stores and intravenous iron delivery could be necessary for patients with hypotransferrinaemia to facilitate erythrocyte precursor iron uptake. This may further influence the management of iron therapy in CKD anemia. Responsiveness to ESA might also differ according to iron profiles. Morbidity/mortality rates are higher for patients with high ESA doses. In particular, the safety and utility of increasing these ESA doses might vary by iron profile.

Information about access to the NephroTest data appears on the French website describing all on-going cohorts in France: https://epidemiologie-france.aviesan.fr/catalog/search.jsp

Supporting Information

Figure S1 Distribution of Hb, transferrin saturation (TSAT), ferritin and transferrin iron binding capacity (TIBC). (TIF)

Acknowledgments

The NephroTest study group collaborators also include P. Houillier, E. Letavernier, P. Urena, G. Maruani, M. Vallet, J.P.H. Rougier, E. Rondeau, P. Romeo, E. Plaisier, H. Fessi, C. Descamps, R. de La Faille, S. Dautheville, E. Daugas, C. d Anzac, M. A. Costa and J. Bouet.

Author Contributions

Conceived and designed the experiments: LM MM M. Froissart BS. Performed the experiments: M. Flamant JPH JRB M. Froissart FV CG MM ET. Analyzed the data: LM MM. Wrote the paper: LM MM BS.

References

1. Moranne O, Froissart M, Rosset J, Gauci C, Boffa JJ, et al. (2009) Timing of onset of CKD-related metabolic complications. J Am Soc Nephrol 20(1): 164–71
2. Herzog CA, Muster HA, Li S, Collins MS (2004) Impact of congestive heart failure, chronic kidney disease, and anemia on survival in the Medicare population. Journal of Cardiac Failure 10(6): 467–472
3. Mercadal L, Metzger M, Casadevall N, Haymann JP, Karras A, et al. and NephroTest Study Group (2012) Timing and determinants of erythropoietin deficiency in chronic kidney disease. Clin J Am Soc Nephrol 7(1): 35–42
4. Stancu S, Stanciu A, Zugravu A, Bârsan L, Dumitru D, et al. (2010) Bone marrow iron, iron indices and the response to intravenous iron in patients with non-dialysis-dependent CKD. Am J Kidney Dis 55: 639–647
5. Fashbave S, Pollack S, Feldman HE, Joffe MM (2009) Iron indices in chronic kidney disease in the National Health and Nutrition Examination Survey 1988–2004. Clin J Am Soc Nephrol 4(1): 57–61
6. Fernandez-Rodriguez AM, Gaudeme-Casasas MC, Molero-Labarta T, Dominguez-Cabreria C, Hortals-Cas NL, et al. (1999) Diagnosis of iron deficiency in chronic renal failure. Am J Kidney Dis 33(4): 508–13
7. Beguin Y, Chenuis CK, Pootrakul P, Fillet G (1993) Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. Blood 81(4): 1067–1076
8. KDIGO clinical practice guidelines. Anemia (2012) Kidney Int supplement 2(4), 1–13
9. Bermejo F, Garcia-Lopez S (2009) A guide to diagnosis of iron deficiency and iron deficiency anemia in digestive diseases. World J Gastroenterol 15(37): 4638–4643
10. Lipschitz DA, Cook JD, Finch CA (1999) A clinical evaluation of serum ferritin as an index of iron stores. 1974. Nutrition 16(6):443–8
11. McFarlane SI, Chen SC, Whaley-Connell AT, Sowers JR, Vassalotti JA, et al. on behalf of the Kidney Early Evaluation Program Investigators (2008) Prevalence and associations of anemia of CKD: Kidney Early Evaluation Program (KEEP) and national health and Nutrition Examination Survey (NHANES) 1999–2004. Am J Kidney Dis 51(2): S66–S55
12. Sawhney MS, Lipato T, Nelson DB, Lederle FA, Rector TS, et al. (2007) Should patients with anemia and low normal or normal serum ferritin undergo colonoscopy? J Am gastroenterology 102(1):82–8
13. White DL (1991) Can serum ferritin be effectively interpreted in the presence of the acute-phase response? Clin Chem 37: 484–485
14. Rawat R, Stoltzfus RJ, Ntouzis R, Mutasa K, Illif PJ, et al. (2009) Influence of inflammation as measured by tPA acid glycoprotein on iron status indicators among HIV-positive postpartum Zimbabwean women. European Journal of Clinical Nutrition 63: 797–799
15. Hsu CY, McCulloch CE, Curhan GC (2002) Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 13(2):504–10
16. Ashby DR, Gale DP, Bushbridge M, Murphy KG, Duncan ND, et al. (2009) Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 75(5): 976–81
17. Bros R, Zitterkopf J, Fitha J, Benner D, Rambold M, et al. (2009) Association of serum total iron-binding capacity and its change over time with nutritional and clinical outcomes in hemodialysis patients. Am J Nephrol 29: 517–581
18. Kalantar-Zadeh K, Kleinert M, Dumme E, Ahem K, Nelson M, et al. (1998) Total iron-binding capacity–estimated transferrin correlates with the nutritional subjective global assessment in hemodialysis patients. Am J Kidney Dis 31 (2): 263–272
19. Prinsen BHC, De Sain-van der velden, Kaysen GA, Straver HWH, Van Rijn HJM, et al. (2001) Transferrin synthesis is increased in nephritic patients insufficiently to replace urinary loss. J Am Soc Nephrol 12: 1017–1025
20. Zang AS, Enns CA (2009) Iron homeostasis: recently identified proteins provide insight into novel control mechanisms. J Biol chemistry 284: 711–715
21. Kopple JD, Greene T, Chumlea WC, Hollinger DW, Maroni BJ, et al. with Modification of the diet in renal disease study group (2000) Relationship between nutritional status and the glomerular filtration rate: results from the MDRD study. Kidney Int 57: 1608–1703
22. Huggenvik JI, Craven CM, Idzerda RL, Bernstein S, Kaplan J, et al. (1989) A splicing defect in the mouse transferrin gene leads to congenital atransferrinemia. Blood 74(1):482–6
23. Fraenkel PG, Gilbert Y, Holzheimer JL, Lattanzi VJ, Burnett SF, et al. (2009) Transferrin-a modulates hepcidin expression in zebrafish embryos. Blood 113(12): 2843–50
24. Goya N, Miyazaki S, Kodate S, Ushio B (1972) A family of congenital atransferrinemia. Blood 40: 239–245
25. Trombini P, Colica T, Nemeth E, Mariani R, Ganz T, et al. (2007) Effects of plasma transfusion on hepcidin production in human congenital hypotransferrinemia. Haematologica 92: 1407–1410
26. Bartnikas TB, Andrews NC, Fleming MD (2011) Transferrin is a major determinant of hepcidin expression in hypotransferrinemic mice. Blood 117(2): 630–637